Dublin, Oct. 10, 2017 -- The "Therapeutic Drug Monitoring - Technologies, Markets, and Companies" report from Jain PharmaBiotech has been added to Research and Markets' offering.
This report deals with therapeutic drug monitoring, a multi-disciplinary clinical specialty, aimed at improving patient care by monitoring drug levels in the blood to individually adjust the dose of drugs for improving outcome.
TDM is viewed as a component of personalized medicine that interacts with several other disciplines including pharmacokinetics and pharmacogenetics. One chapter is devoted to monitoring of drugs of abuse (DoA). Various technologies used for well-known DoA are described. A section on drug abuse describes methods of detection of performance-enhancing drugs.
TDM market is analyzed from 2016 to 2026 according to technologies as well as geographical distribution. Global market for DoA testing was also analyzed from 2016 to 2026 and divided according to the area of application. Unmet needs and strategies for development of markets for TDM are discussed.
The report contains profiles of 35 companies involved in developing tests and equipment for drug monitoring along with their collaborations. The text is supplemented with 21 tables, 9 figures and 210 selected references from literature.
Benefits of this report
- Up-to-date one-stop information on therapeutic drug monitoring
- Description of 35 companies involved with their collaborations in this area
- Market analysis 2016-2026
- Market values in major regions
- Strategies for developing markets for therapeutic drug monitoring
- A selected bibliography of 210 publications
- Text is supplemented by 21 tables and 9 figures
Who should read this report?
- Biotechnology companies developing assays and equipment for drug monitoring
- Reference laboratories providing drug monitoring services
- Pharmaceutical companies interested in companion tests for monitoring their drugs
- Clinical pharmacologists interested in integrating therapeutic drug monitoring with pharmacogenetics for development of personalized medicine
Key Topics Covered:
Executive Summary
1. Introduction
2. Technologies for TDM
3. Drug Monitoring Instruments
4. Applications of TDM
5. Drugs Requiring Monitoring
6. Monitoring of Biological Therapies
7. Monitoring of Drug Abuse
8. Markets for TDM
9. Companies
10. References
For more information about this report visit https://www.researchandmarkets.com/research/hzksfx/therapeutic_drug
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Drug Discovery


Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 



